Compare CBIO & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | BYND |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Packaged Foods |
| Sector | | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.7M | 446.9M |
| IPO Year | N/A | 2019 |
| Metric | CBIO | BYND |
|---|---|---|
| Price | $10.83 | $0.84 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 7 |
| Target Price | ★ $27.17 | $1.70 |
| AVG Volume (30 Days) | 142.5K | ★ 52.1M |
| Earning Date | 02-23-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $290,565,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.81 | $0.50 |
| 52 Week High | $21.40 | $7.69 |
| Indicator | CBIO | BYND |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 37.55 |
| Support Level | $10.56 | $0.90 |
| Resistance Level | $14.71 | $1.02 |
| Average True Range (ATR) | 1.01 | 0.07 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 6.14 | 0.43 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.